Porfimer Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Non-Small Cell Lung Cancer

2 mg/kg IV as a single slow intravenous injection over 3 to 5 minutes. Illumination with laser light 40 to 50 hours following injection with porfimer constitutes the second stage of therapy. A second laser light application may be given 96 to 120 hours after injection, preceded by gentle debridement of residual tumor.

Patients may receive a second course of porfimer a minimum of 30 days after the initial therapy; up to three courses of porfimer (each separated by a minimum of 30 days) can be given.

Usual Adult Dose for Esophageal Carcinoma

2 mg/kg IV as a single slow intravenous injection over 3 to 5 minutes. Illumination with laser light 40 to 50 hours following injection with porfimer constitutes the second stage of therapy. A second laser light application may be given 96 to 120 hours after injection, preceded by gentle debridement of residual tumor.

Patients may receive a second course of porfimer a minimum of 30 days after the initial therapy; up to three courses of porfimer (each separated by a minimum of 30 days) can be given.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

The influence of impaired hepatic function on porfimer disposition has not been evaluated.

Precautions

All patients who receive porfimer will be photosensitive and must observe precautions to avoid exposure of skin and eyes to direct sunlight or bright indoor light (from examination lamps, including dental lamps, operating room lamps, unshaded light bulbs at close proximity, etc.) for at least 30 days. Some patients may remain photosensitive for up to 90 days or more.

Conventional UV (ultraviolet) sunscreens are of no value in protecting against photosensitivity reactions because photoactivation is caused by visible light.

Ocular discomfort, commonly described as sensitivity to sun, bright lights, or car headlights, has been reported in patients who received porfimer. For 30 days, when outdoors, patients should wear dark sunglasses which have an average white light transmittance of <4%.

As a result of PDT treatment, patients may complain of substernal chest pain because of inflammatory responses within the area of treatment.

Patients with endobronchial lesions must be closely monitored between the laser light therapy and the mandatory debridement bronchoscopy for any evidence of respiratory distress. Inflammation, mucositis, and necrotic debris may cause obstruction of the airway. If respiratory distress occurs, the physician should be prepared to carry out immediate bronchoscopy to remove secretions and debris to open the airway.

Women of childbearing potential should practice an effective method of contraception during therapy.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Dialysis

Data not available

Other Comments

The reconstituted product should be protected from bright light and used immediately.

Hide
(web2)